Severance hospital
Seoul, Seodaemun-gu, South Korea
NCT Number: NCT01504984
The purpose of this study is to evaluate the pharmacokinetics equivalence and safety by comparing pharmacokinetics characteristics between the SYO-1126 and Glivec Film Coated tab 4T (400mg) when administered a single-dose to healthy male volunteers.
Looking for future studies?
Notify Me20 year–45 year
Male
Interventional
Phase 1
Seoul, Seodaemun-gu, South Korea
Healthy volunteers are administrated single-dose over the period I and II (crossover) of SYO-1126 and Glivec Film Coated tab 4T (400mg) as of imatinib 400mg.
Every time before and after each medication, pharmacokinetic (PK) parameters and safety of SYO-1126 and Glivec Film Coated tab 4T (400mg) is performed using a blood sample and conducting some tests (vital signs, physical exam, ECG, laboratory test, etc.) respectively.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Imatinib 400mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
Other names: Imatinib 400mg
Imatinib 100mg/tablet, PO, 4 tablets once daily for period I&II D1(crossover)
Other names: Imatinib 100mg, Glivec film coated tab
Time frame: 0-72hr
Time frame: 0-72hr
Time frame: 0-72hr
Time frame: 20~24 days
Time frame: 0-72hr
Time frame: 0-72hr
Time frame: 0-72hr
Samyang Biopharmaceuticals Corporation
Industry
An Open-label, Randomized, Single Dose, Crossover Phase I Clinical Trial to Compare Pharmacokinetic Property of SYO-1126 and Glivec Film Coated Tab., 4T (400mg) in Healthy Male Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details